Different models for oral anticoagulation management may be applied provided that minimal assistance criteria are fulfilled: An italian experience

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 6, 2009, Pages 568-573

  Prisco, Domenico ^a,b   Antonucci, Emilia ^a   Grifoni, Elisa ^a   Mazzaglia, Giampiero ^c   Bellandi, Tommaso ^d   Tartaglia, Riccardo ^d   Poli, Daniela ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Regional Agency for Healthcare Services of Tuscany   (Italy)

^d Center for Clinical Risk Management and Patient Safety   (Italy)

Author keywords

Health care services; Oral anticoagulant therapy; Patient safety; Quality of care

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIVITAMIN K; CARDIOVASCULAR AGENT; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD SAMPLING; CLINICAL EVALUATION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FOLLOW UP; FOOD DRUG INTERACTION; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ITALY; LABORATORY DIAGNOSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK MANAGEMENT; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; HUMANS; ITALY; MIDDLE AGED; PATIENT COMPLIANCE; RISK MANAGEMENT; SELF CARE; THROMBOSIS; YOUNG ADULT;

EID: 70449416163     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1240017     Document Type: Review

References (9)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 (6, suppl) 160S-198S (Pubitemid 351892967)
2. Ansell J E., Buttaro M L., Thomas O V., Knowlton C H. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ann Pharmacother 1997 31 (5) 604-615
3. Palareti G, Legnani C, Guazzaloca G et al, ad hoc Study Group of the Italian Federation of Anticoagulation Clinics. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005 129 (1) 72-78 (Pubitemid 40524054)
4. Vincent C. Understanding and responding to adverse events. N Engl J Med 2003 348 (11) 1051-1056
5. Gasse C, Hollowell J, Meier C R., Haefeli W E. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005 94 (3) 537-543
6. Holbrook A M., Pereira J A., Labiris R et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005 165 (10) 1095-1106
7. Giunta Regionale Toscana. Deliberazione n. 46 January 28, 2008. Indirizzi alle aziende sanitarie per la gestione della qualità e della sicurezza nella terapia anticoagulante orale (TAO). Bollettino Ufficiale Regione Toscana 2008 6
8. Kravitz R L., Melnikow J. Engaging patients in medical decision making. BMJ 2001 323 (7313) 584-585
9. Vincent C A., Coulter A. Patient safety: what about the patient? Qual Saf Health Care 2002 11 (1) 76-80